KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Equity Ratio (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Equity Ratio for 18 consecutive years, with 0.77 as the latest value for Q1 2026.

  • For Q1 2026, Equity Ratio fell 1.77% year-over-year to 0.77; the TTM value through Mar 2026 reached 0.77, down 1.77%, while the annual FY2025 figure was 0.77, 0.87% down from the prior year.
  • Equity Ratio hit 0.77 in Q1 2026 for Regeneron Pharmaceuticals, roughly flat from 0.77 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.79 in Q1 2024 and bottomed at 0.76 in Q1 2022.
  • Average Equity Ratio over 5 years is 0.78, with a median of 0.78 recorded in 2024.
  • Year-over-year, Equity Ratio grew 12.15% in 2022 and then decreased 1.77% in 2026.
  • Regeneron Pharmaceuticals' Equity Ratio stood at 0.78 in 2022, then rose by 1.21% to 0.79 in 2023, then dropped by 0.99% to 0.78 in 2024, then dropped by 0.87% to 0.77 in 2025, then fell by 0.23% to 0.77 in 2026.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.77, 0.77, and 0.77 for Q1 2026, Q4 2025, and Q3 2025 respectively.